Volume 5B - Army Financial Management - U.S. Army

More documents

Recommendations

Info

UNCLASSIFIEDExhibit R-4A, RDT&E Schedule Details: PB 2012 Army DATE: February 2011APPROPRIATION/BUDGET ACTIVITY2040: Research, Development, Test & Evaluation, ArmyBA 5: Development & Demonstration (SDD)R-1 ITEM NOMENCLATUREPE 0604807A: Medical Materiel/MedicalBiological Defense Equipment - Eng DevPROJECT832: Field Medical Systems EngineeringDevelopmentSchedule DetailsStartEndEvents Quarter Year Quarter Year(1) Ceramic Oxygen Gen Sys (MS-C) 3 2010 3 2010(6) Ultrasonic Brain Imager (MS-C) 1 2010 1 2010Total Intravenous Anesthesia (TIVA) (MS-C) 4 2012 4 2012Burn Resuscitation Decision Device (MS-C) 1 2012 1 2012Wireless Medical Monitoring (MS-C) 3 2012 3 2012Plasma Knife (MS-C) 1 2012 1 2012UNCLASSIFIEDArmy Page 16 of 27 R-1 Line Item #111Volume 5B - 209
UNCLASSIFIEDExhibit R-2A, RDT&E Project Justification: PB 2012 Army DATE: February 2011APPROPRIATION/BUDGET ACTIVITY2040: Research, Development, Test & Evaluation, ArmyBA 5: Development & Demonstration (SDD)COST ($ in Millions)FY 2010 FY 2011FY 2012BaseR-1 ITEM NOMENCLATUREPE 0604807A: Medical Materiel/MedicalBiological Defense Equipment - Eng DevFY 2012OCOPROJECT849: INFEC DIS DRUG/VACC EDFY 2012Total FY 2013 FY 2014 FY 2015 FY 2016Cost ToComplete Total Cost849: INFEC DIS DRUG/VACC ED 13.193 12.227 8.487 - 8.487 13.631 14.728 15.131 15.178 Continuing ContinuingQuantity of RDT&E ArticlesA. Mission Description and Budget Item JustificationThis project funds development of candidate medical countermeasures for militarily relevant infectious diseases. These products fall within four major areas: vaccines,drugs, diagnostic kits/devices, and insect control measures to limit exposure and disease transmission. It funds research that supports conclusive human clinicaltrials for large-scale human efficacy testing, expanded human safety clinical trials, long-term animal studies, and related manufacturing tests. This work, which isjointly performed by military laboratories, civilian contracted pharmaceutical firms and foreign research partners, is directed toward the prevention of disease, earlydiagnosis, and speeding recovery once diagnosed. Medical products approved for human use must successfully complete a series of clinical trials that are requiredand regulated by the U.S. Food and Drug Administration (FDA). FDA approval is a mandatory obligation for all military products placed into the hands of medicalproviders or service members for human use. Development priority is based upon four major factors: (1) the extent of the disease within the Combatant Commands'theater of operations, (2) the clinical severity of the disease, (3) the technical maturity of the proposed solution, and (4) the affordability of the solution (development,production, and sustainment). Malaria, dysentery, hepatitis, and dengue diseases (a severe debilitating disease transmitted by mosquitoes), which are found in AfricaCommand, Central Command, European Command, Southern Command, and Pacific Command areas are at the top of the infectious diseases requirements list.B. Accomplishments/Planned Programs ($ in Millions, Article Quantities in Each) FY 2010 FY 2011 FY 2012Title: FY 10 Malaria Drug/ Vaccine Engineering DevelopmentDescription: This project funds in FY 10 development of candidate medical countermeasures for militarily relevant infectiousdiseases.Articles:FY 2010 Accomplishments:Conducted clinical trials, developmental testing, and reviews of malarial/antimalarial vaccines, drugs, diagnostics and insectrepellents. For Tafenoquine, conducted data analysis and prepared a final report on the small human challenge clinical trial, andbegan pre-trial activities for a large-scale safety/efficacy human clinical trial (treatment indication) in a malaria endemic country.6.01804.5680-FY 2011 Plans:Will conduct clinical trials, developmental testing, and reviews of malarial/antimalarial vaccines, drugs, diagnostics and insectrepellents. For Tafenoquine, will complete pre-trial activities for a large-scale safety/efficacy human clinical trial (treatmentindication) in a malaria endemic country.Title: FY 10 Infectious Disease Drug and Vaccine Engineering DevelopmentArticles:7.17507.65908.487UNCLASSIFIEDArmy Page 17 of 27 R-1 Line Item #111Volume 5B - 210
Page 1 and 2:
UNCLASSIFIEDDepartment of DefenseFi
Page 3 and 4:
UNCLASSIFIEDFY 2012 RDT&E, ARMYPROG
Page 5 and 6:
Tractor Eggs0603131/DS9*High Perfor
Page 7 and 8:
UNCLASSIFIEDDepartment of the ArmyF
Page 9 and 10:
Appropriation: 2040 ALineNoProgramE
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
UNCLASSIFIEDArmy • President's Bu
Page 19 and 20:
UNCLASSIFIEDArmy • President's Bu
Page 21 and 22:
BA# 05: Development & Demonstration
Page 23 and 24:
UNCLASSIFIEDExhibit R-2, RDT&E Budg
Page 25 and 26:
UNCLASSIFIEDExhibit R-2A, RDT&E Pro
Page 27 and 28:
Page 29 and 30:
UNCLASSIFIEDExhibit R-3, RDT&E Proj
Page 31 and 32:
UNCLASSIFIEDExhibit R-4, RDT&E Sche
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
UNCLASSIFIEDExhibit R-4A, RDT&E Sch
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180: UNCLASSIFIEDExhibit R-2A, RDT&E Pro
Page 183 and 184: UNCLASSIFIEDExhibit R-4, RDT&E Sche
Page 185 and 186: UNCLASSIFIEDExhibit R-2, RDT&E Budg
Page 191 and 192: UNCLASSIFIEDExhibit R-3, RDT&E Proj
Page 229: UNCLASSIFIEDExhibit R-4, RDT&E Sche
Page 237 and 238: UNCLASSIFIEDExhibit R-4A, RDT&E Sch
Page 261 and 262: UNCLASSIFIEDExhibit R-4A, RDT&E Sch
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
Page 325 and 326:
Page 327 and 328:
Page 329 and 330:
Page 331 and 332:
Page 333 and 334:
Page 335 and 336:
Page 337 and 338:
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Page 359 and 360:
Page 361 and 362:
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
Page 371 and 372:
Page 373 and 374:
Page 375 and 376:
Page 377 and 378:
Page 379 and 380:
Page 381 and 382:
Page 383 and 384:
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
Page 405 and 406:
Page 407 and 408:
Page 409 and 410:
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
Page 419 and 420:
Page 421 and 422:
Page 423 and 424:
Page 425 and 426:
Page 427 and 428:
Page 429 and 430:
Page 431 and 432:
Page 433 and 434:
Page 435 and 436:
Page 437 and 438:
Page 439 and 440:
Page 441 and 442:
Page 443 and 444:
Page 445 and 446:
Page 447 and 448:
Page 449 and 450:
Page 451 and 452:
Page 453 and 454:
Page 455 and 456:
Page 457 and 458:
Page 459 and 460:
Page 461 and 462:
Page 463 and 464:
Page 465 and 466:
Page 467 and 468:
Page 469 and 470:
Page 471 and 472:
Page 473 and 474:
Page 475 and 476:
Page 477 and 478:
Page 479 and 480:
Page 481 and 482:
Page 483 and 484:
Page 485 and 486:
Page 487 and 488:
Page 489 and 490:
Page 491 and 492:
Page 493 and 494:
Page 495 and 496:
Page 497 and 498:
Page 499 and 500:
Page 501 and 502:
Page 503 and 504:
Page 505 and 506:
Page 507 and 508:
Page 509 and 510:
Page 511 and 512:
Page 513 and 514:
Page 515 and 516:
Page 517 and 518:
Page 519 and 520:
Page 521 and 522:
Page 523 and 524:
Page 525 and 526:
Page 527 and 528:
Page 529 and 530:
Page 531 and 532:
Page 533 and 534:
Page 535 and 536:
Page 537 and 538:
Page 539 and 540:
Page 541 and 542:
Page 543 and 544:
show all

Volume 5B - Army Financial Management - U.S. Army

Create successful ePaper yourself

Delete template?

Save as template?